PriceTargets.com logo

OS Therapies - OSTX Stock Price Target and Predictions

  • Consensus Rating: Strong Buy
  • Consensus Price Target: $17.50
  • Forecasted Upside: 980.25%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 2 Strong Buy Ratings
$1.62 As of 03/28/2025 05:00 PM ET
+0 (0.00%)

This chart shows the closing price for OSTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
FebMar$1.62Closing price on 03/29/25:
Get New OS Therapies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OSTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OSTX

Analyst Price Target is $17.50
▲ +980.25% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for OS Therapies in the last 3 months. The average price target is $17.50, with a high forecast of $20.00 and a low forecast of $15.00. The average price target represents a 980.25% upside from the last price of $1.62.

This chart shows the closing price for OSTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
8/2410/241/253/254/26$1.01$5.76$11$15$20Closing price on 03/29/25: $1.62High$20.00Average$17.50Low$15.00




Current Consensus is Strong Buy

The current consensus among 4 contributing investment analysts is to buy (strong buy) stock in OS Therapies.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/7/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/5/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2024
  • 2 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2024
  • 2 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2024
  • 2 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/28/2025
  • 2 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2025

Latest Recommendations

  • 2 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/20/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
1/30/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
1/16/2025Maxim GroupBoost TargetBuy ➝ Buy$8.00 ➝ $15.00
1/15/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
11/26/2024Maxim GroupInitiated CoverageBuy$8.00
9/3/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
8/22/2024Brookline Capital ManagementUpgradeStrong-Buy
(Data available from 3/30/2020 forward)

News Sentiment Rating

0.26 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/30/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2024
  • 3 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
1/29/2025
  • 3 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
2/28/2025
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
3/30/2025

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

OS Therapies logo
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
Read More

Today's Range

Now: $1.62
Low: $1.54
High: $1.65

50 Day Range

MA: $1.92
Low: $1.44
High: $3.12

52 Week Range

Now: $1.62
Low: $1.41
High: $7.00

Volume

66,283 shs

Average Volume

517,990 shs

Market Capitalization

$35.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of OS Therapies?

The following Wall Street sell-side analysts have issued research reports on OS Therapies in the last twelve months: Brookline Capital Management, D. Boral Capital, EF Hutton Acquisition Co. I, and Maxim Group.
View the latest analyst ratings for OSTX.

What is the current price target for OS Therapies?

0 Wall Street analysts have set twelve-month price targets for OS Therapies in the last year. Their average twelve-month price target is $17.50, suggesting a possible upside of 980.2%. D. Boral Capital has the highest price target set, predicting OSTX will reach $20.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $15.00 for OS Therapies in the next year.
View the latest price targets for OSTX.

What is the current consensus analyst rating for OS Therapies?

OS Therapies currently has 2 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Strong Buy."
View the latest ratings for OSTX.

What other companies compete with OS Therapies?

Other companies that are similar to OS Therapies include Larimar Therapeutics, Compugen, Zentalis Pharmaceuticals, Actuate Therapeutics and Organigram. Learn More about companies similar to OS Therapies.

How do I contact OS Therapies' investor relations team?

OS Therapies' physical mailing address is 15825 SHADY GROVE ROAD, SUITE 135, ROCKVILLE, MD, 20850. The company's listed phone number is (410) 297-7793 and its investor relations email address is jld@ostherapies.com. The official website for OS Therapies is ostherapies.com. Learn More about contacing OS Therapies investor relations.